Acalabrutinib in patients with Relapsed/Refractory and Treatment naïve deletion 17p CLL/SLL

Trial Identifier:	15-H-0016
Sponsor:	AcertaPharma
Collaborator:	NIH
NCTID::	NCT02337829
Start Date:	January 2015
Primary Completion Date:	June 2020
Study Completion Date:	December 2025
Condition:	CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States of America, MD	Bethesda, MD, United States of America, 20892

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.